Results 211 to 220 of about 13,195 (282)

DNA-Programmable Protein Degradation: Dynamic Control of Proteolysis-Targeting Chimera Activity via DNA Hybridization and Strand Displacement. [PDF]

JACS Au
Kashyap D, Haider S, Milne TA, Booth MJ.
europepmc   +1 more source

G4‐Ligand‐Directed PROTACs Unveil DR1 as a Novel Ligand‐Co‐Binding G4‐Protein and Reshape G4‐Dependent Transcription

Advanced Science, Volume 13, Issue 27, 13 May 2026.
G4‐binding proteins (G4BPs) that specifically co‐bind G4s in the presence of small‐molecule ligands represent a critical but unexplored class of proteins. We introduce G4‐Ligand‐Directed PROTACs (G4L‐TACs), a chemical platform that couples G4 ligands (PDS) to E3 recruiters to selectively degrade these ligand‐co‐binding G4BPs.
Mao‐Lin Li, Shu‐Min Xu, Xin‐Chen Jiang, Le‐Tian Dai, Yu‐Tao Hu, Kai‐Bo Wang, Jia‐Heng Tan, Zhi‐Shu Huang, Shuo‐Bin Chen   +8 more
wiley   +1 more source

Targeted protein degradation of PDE4 shortforms by a novel proteolysis targeting chimera. [PDF]

FEBS J
Sin YY, Giblin A, Judina A, Rujirachaivej P, Corral LG, Glennon E, Tai ZX, Feng T, Torres E, Zorn A, Gorelik J, Kyurkchieva E, Yenchitsomanus PT, Swindlehurst C, Chan K, Stirling D, Baillie GS.   +16 more
europepmc   +1 more source

Membrane translocation and refolding mitochondrial proteins [PDF]

, 1990
Hartl, Franz-Ulrich, Neupert, Walter, Srere, Paul A.   +2 more
core  

Cucurbit[7]uril‐Based Plug‐and‐Play Platform on Bacterial Surfaces for Constructing Functional Supramolecular Biohybrids

Aggregate, Volume 7, Issue 5, May 2026.
This study establishes a supramolecular “plug‐and‐play” platform on bacterial surfaces via cucurbit[7]uril host–guest chemistry. The platform successfully generates functional biohybrids for fluorescence imaging, drug delivery, and in vivo bioorthogonal catalysis, demonstrating its potential for functional living materials with broad biomedical ...
Fang Huang, Jun Zhu, Bingfa Wu, Xinyuan Sun, Linghong Huang, Yiliu Liu   +5 more
wiley   +1 more source

Rational Design and Optimization of a Potent IDO1 Proteolysis Targeting Chimera (PROTAC). [PDF]

J Med Chem
Monsen PJ, Bommi PV, Grigorescu AA, Lauing KL, Mao Y, Berardi P, Zhai L, Ojo O, Penco-Campillo M, Koch T, Egozi M, Jha S, Dunne SF, Jiang H, Song G, Zhang F, Kregel S, Vaziri-Gohar A, Fanning SW, Sanchez-Gomez P, Allen JM, Yamini B, Lukas RV, Wainwright DA, Schiltz GE.   +24 more
europepmc   +1 more source

Conjugated 2′‐Fucosyllactose–Potato Protein Hydrolysate as Novel Prebiotics

Food Frontiers, Volume 7, Issue 3, May 2026.
This study introduces a novel protein‐containing prebiotic based on 2′‐FL‐PPH Maillard conjugates micelles that co‐deliver proteins and carbohydrates to the colon to selectively nourish colonic probiotics. These digestion‐resistant micelles enhanced Bifidobacteria, SCFAs, gut barrier integrity, and metabolic health more effectively than conventional ...
Stav Peled, May Cohen‐Hakmon, Ravit Edelman, Yechezkel Kashi, Yoav D. Livney   +4 more
wiley   +1 more source

Preparation and Characterization of Ternary Complexes to Improve the Solubility and Dissolution Performance of a Proteolysis-Targeting Chimera Drug. [PDF]

Pharmaceutics
Zhang H, Wu H, Wang L, Galarza LM, Wu C, Li M, Wang Z, Zhou E, Han J.   +8 more
europepmc   +1 more source

From Platelet Toxicity to Precision Targeting: Evolving Strategies to Overcome Thrombocytopenia in BCL‐2/BCL‐XL Inhibition

Health Science Reports, Volume 9, Issue 5, May 2026.
ABSTRACT Background Simultaneous blockade of the anti‐apoptotic proteins BCL‐2 and BCL‐XL has been shown to be efficacious in preclinical and clinical trials for tumors that are co‐dependent on their survival pathways, although clinical development has been limited owing to dose‐limiting thrombocytopenia associated with BCL‐XL inhibition.
Md Mohiuddin
wiley   +1 more source

Preclinical Evaluation of Bavdegalutamide (ARV-110), a Novel PROteolysis TArgeting Chimera Androgen Receptor Degrader. [PDF]

Mol Cancer Ther
Snyder LB, Neklesa TK, Willard RR, Gordon DA, Pizzano J, Vitale N, Robling K, Dorso MA, Moghrabi W, Landrette S, Gedrich R, Lee SH, Taylor ICA, Houston JG.   +13 more
europepmc   +1 more source